Format

Send to

Choose Destination
Hepatology. 2009 Nov;50(5):1453-63. doi: 10.1002/hep.23143.

Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma.

Author information

1
Department of Surgery and Center for Cancer Research, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong.

Erratum in

  • Hepatology. 2010 Jan;51(1):358.

Abstract

Hepatocellular carcinoma (HCC) is a lethal malignancy for which there are no effective therapies. To develop rational therapeutic approaches for treating this disease, we are performing proof-of-principle studies targeting molecules crucial for the development of HCC. Here, we show that cadherin-17 (CDH17) adhesion molecule is up-regulated in human liver cancers and can transform premalignant liver progenitor cells to produce liver carcinomas in mice. RNA interference-mediated knockdown of CDH17 inhibited proliferation of both primary and highly metastatic HCC cell lines in vitro and in vivo. The antitumor mechanisms underlying CDH17 inhibition involve inactivation of Wnt signaling, because growth inhibition and cell death were accompanied by relocalization of beta-catenin to the cytoplasm and a concomitant reduction in cyclin D1 and an increase in retinoblastoma.

CONCLUSION:

Our results identify CDH17 as a novel oncogene in HCC and suggest that CDH17 is a biomarker and attractive therapeutic target for this aggressive malignancy.

PMID:
19676131
PMCID:
PMC3328302
DOI:
10.1002/hep.23143
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center